NEW YORK, NY -- (Marketwire) -- 04/20/12 -- Mergers and Acquisitions have been a hot topic in the Biotechnology Industry recently. According to a recent report by Dealogic, pharmaceutical deals totaled $18.5 billion globally this year, an increase of 5% from the same period last year. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Human Genome Sciences (NASDAQ: HGSI) and Complete Genomics, Inc. (NASDAQ: GNOM).
Access to full reports can be found at:
As larger companies reduce spending on research and development they are looking at smaller biotech companies to diversify their product lines. M&A allows bigger companies to acquire products and technology that are already proven in the market place, avoiding the many risks associated with research and development.
On Thursday Biotechnology Company Human Genome Sciences rejected a $2.59 billion takeover bid from GlaxoSmithKline. The announcement comes just a day after Swiss pharmaceutical company Roche announced that it was abandoning its bid for U.S. biotech firm Illumina.
Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.
Human Genome Sciences, Inc. recently announced that it will sponsor a conference call to discuss its financial results for the quarter ended March 31, 2012. These results are expected to be disclosed on Wednesday, April 25, 2012, before the capital markets open. The conference call will be hosted by senior management and will be held on Wednesday, April 25, 2012 at 8:00 a.m. Eastern Time.
Complete Genomics is the whole human genome sequencing company that has developed and commercialized an innovative DNA sequencing service. The Complete Genomics Analysis Platform (CGA Platform) combines Complete Genomics' proprietary human genome sequencing technology with advanced informatics and data management software.
Paragon Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Paragon Report has not been compensated by any of the above-mentioned companies. We act as independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.ParagonReport.com/disclaimer